International Speakers at a Glance
- Dr Rob Bristow
- Prof Steven Balk
- Dr James Borin
- Dr William Catalona
- Mr Benjamin Challacombe
- Dr Laurence Klotz
- Prof Jelle Barentsz
- Dr Antonio Finelli
- Dr Laurence Klotz
- Dr Stacy Loeb
- Dr Christian Nelson
- Dr Alan Partin
- A/Prof Monique Roobol
- Dr Oliver Sartor
- Dr Howard Scher
- Dr Jay Smith
- Prof Patrick Walsh
- Dr Carl WIjburg
- Dr Dingwei Ye
A – Z
Dr. Balk received his M.D. and Ph.D. from Harvard Medical School/Harvard-MIT HST Program, and his Medical Oncology training at BIDMC and DFCI. His lab has focused on prostate cancer biology; particularly on functions of androgen receptor (AR) and interacting pathways in prostate cancer, and mechanisms of resistance to AR targeted therapies.
Jelle Barentsz is a recognized excellent international top-researcher. His contribution in MRI of prostate cancer and lymph nodes is of high quality. With his team he develops and validates new MRI-techniques. Especially the translation of the results of his research into daily care makes him extraordinary.
He received, Royal Decoration: “Knight in the Order of the Dutch Lion”, Wertheim Salomonson Medal of the Dutch Radiological Society (NVvR), Lifetime Achievement Award of the SAR, Queen Wilhelmina Research Award of the Dutch Cancer Society, SCBTMR Lauterbur Award.
He received his MD in 1980, and PhD in 1990. He has 222 peer reviewed publications. (http://www.ncbi.nlm.nih.gov/pubmed/?term=Barentsz+J+%5Bau%5D).
His 3 most important contributions are, 1) Rebirth of the macrophages specific nano-MR contrast agent (Combidex ®), 2) Development, validation and implementation of multi-parametric MRI, resulting in the wide-spread use of prostate MRI, and 3) Development plus implementation of the PI-RADS scoring system for structured interpretation of prostate MRI’s.
He is Founding Member and Past-President of the ICIS and Past-President of the ESUR.
Currently he is Professor of Radiology and Chair of the Prostate MR-Reference Center. This centre provides education and quality control and is visited yearly by >3000 patients.
Dr. Barentsz is also respected, because he is an empathetic man, who always puts the patient in the centre. To achieve this goal he does not allow any concessions. His devotion, passion and quality result in visits of many patients from all over the world. Also, international physicians visit his centre, to learn his techniques and implement them in their own practice.
His dream: MRI standard practice in men with elevated PSA, and global approval of Combidex.image guided therapies. It’s his ambition to treat prostate cancer effectively with only minimal side-effects. It is clear that the value of patient care is central within Barentsz’ work.
Dr. Borin completed his urology residency at the Mt. Sinai Medical Center in New York, followed by a fellowship in endourology and robotics at U.C. Irvine. From 2006-2013, he was the Director of Robotic Surgery and Director of the Executive Health Program at the University of Maryland. He recently joined the faculty at New York University, where he is Associate Program Director and head of robotic urology at the Manhattan VA Hospital. His research has focused on technological advancements in the management of prostate cancer, kidney cancer and kidney stones. Dr. Borin serves on the AUA’s Laparoscopic, Robotic and New Surgical Technology Committee and is an AUA representative to the international curriculum development initiative, Fundamentals of Robotic Surgery, and to the Council of Medical Specialty Societies’ Simulation Workgroup.
Dr. Bova completed training in anatomic pathology at Weill-Cornell Medical College, and completed training in urologic surgery at the University of Virginia, followed by a molecular genetics research fellowship at Johns Hopkins. Dr. Bova ‘s main interest is to benefit patients by defining the fundamental nature of lethal metastatic prostate cancer in relation to its nonlethal nonmetastatic counterparts. To this end, Dr. Bova pioneered the development of molecular autopsy studies, and developed research information system software to support such studies that is now used in large institutions and pharmaceutical companies. Dr. Bova is senior principal investigator of the International Cancer Genome Consortium Prostate Cancer UK group, and representative to the Global Alliance for Genomic Health. As Finnish Distinguished Professor in Tampere, Finland, Dr. Bova leads a collaborative group developing an approach to iterative discovery of effective personalized prostate cancer medicine in high risk patients based on genomic findings.
Dr. Bristow is currently a Clinician-Scientist at Princess Margaret Cancer Centre where he is treats genitourinary cancers and Professor within the Departments of Radiation Oncology and Medical Biophysics at the University of Toronto. His primary research interests are in tumour hypoxia, genome instability and prostate cancer genomics in the context of personalized cancer medicine.
Dr. Bristow is the lead PI for the Canadian component of the ICGC whole genome prostate cancer sequencing project (CPC-GENE) and is Head, Campbell Family Research Institute-PMH Prostate Cancer Research Program. He also serves on the Scientific Advisory Board/Committee for Prostate Cancer Canada (co-Chair), the Prostate Cancer Foundation (USA), the Advisory Council for Research (ACOR) of Canadian Cancer Society Research Institute, the Movember Global Strategic Committee and Action Plan (GAP) and the Cancer Research Society. He is past Chair of the Radiation Biology and Cancer Biology Committees of both ASTRO and CARO.
Dr Bristow is Editor of the 5th Edition Basic Science of Oncology and has over 200 published papers and book chapters. Dr Bristow has won a number of awards including the Virginia Logan Lectureship (Thomas Jefferson University), the Picchione Scholar Award (Pathology-Dalhousie University), Vivian Sakyly Visiting Professor (Oncology-McGill University) and the John F Ferguson Prostate Cancer Hero Award (Prostate Cancer Canada). He has also won numerous teaching and mentorship awards including the best Postgraduate Teacher at the University of Toronto’s Faculty of Medicine in 2011. He is twice a Canadian Foundation for Innovation (CFI) awardee. He was made a Canadian Cancer Society Research Scientist in 2004 and an ESTRO Honorary Fellow in 2011.
Dr. Catalona joined the Northwestern faculty in 2003. He is known for having been the first to show that a simple blood test that measures levels of prostate-specific antigen (PSA) is the most accurate method for detecting prostate cancer and for having developed the “free” PSA test as a means of improving the accuracy of prostate cancer screening.Dr. Catalona is currently conducting research into the genetics of prostate cancer which could lead to new tests for the disease as well as possible new means of treating or preventing prostate cancer. He specializes in prostate cancer surgery and is recognized as an expert in performing the “nerve-sparing” radical prostatectomy that can preserve sexual potency.In addition to his appointment as Professor of Urology, Dr. Catalona also serves as Director of the Clinical Prostate Cancer Program of Northwestern’s Robert H. Lurie Comprehensive Cancer Center.
Urologist, Guy’s Hospital, United Kingdom
Consultant Urological Surgeon and Honorary Senior Lecturer with a special interest in robotic surgery and minimally invasive prostate cancer treatments. Ben is associate editor of the BJUI, with over 140 peer-reviewed publications and 20 book chapters on minimally invasive and robotic urological techniques. He has performed over 400 robotic radical prostatectomies, 160 robotic partial nephrectomies and also performs dynamic prostate brachytherapy and holmium laser prostatectomy (HoLEP) within the Guy’s Urology Centre.His current research interests are in robotic surgery training, trans-perineal template biopsy techniques, active surveillance of low risk prostate cancer, sentinel lymph node techniques and haptic probe development in robotic surgery.
Princess Margaret Hospital, Canada
Dr. Finelli is the GU cancer site lead at the Princess Margaret Hospital. He conducts health services research and has published more than 100 manuscripts. His clinical practice focuses on the management of prostate and kidney cancer. He has performed live surgery for instruction in more than 10 countries and is recognized internationally for his contributions to minimally invasive surgery. Dr. Finelli has recently been selected as the inaugural Genitourinary Cancer Lead for the province of Ontario.
Sunnybrook Health Sciences Centre, Canada
Dr. Laurence Klotz, MD serves as Chief of Urology at Sunnybrook Health Sciences Centre, and is a globally-renowned clinician in the area of Uro-oncology. Dr. Klotz serves as a Member of Clinical Advisory Board at Profound Medical Inc. He serves as President of the Canadian Urological Association and the Canadian Urology Research Consortium, Chairman of the World Uro-Oncology Federation, and the Editor-in-Chief of the Canadian Journal of Urology.
Dr. Klotz’s laboratory has been studying the effect of selected micronutrients—particularly vitamin E, selenium and lycopene—in the prevention of prostate cancer. In a preclinical model, which spontaneously develops prostate cancer by eight months of age, his team has demonstrated that supplementing food with these micronutrients results in a dramatic and profound reduction in the development of these cancers. The major thrust of Dr. Klotz’s research is to analyze the mechanisms by which these cancers are prevented.
Dr. Stacy Loeb is an Assistant Professor of Urology and Population Health at New York University (NYU), specializing in prostate cancer. Dr. Loeb attended medical school at Northwestern University and completed her urology residency training at Johns Hopkins. She has published over 220 peer-reviewed articles and 8 book chapters on prostate cancer. Dr. Loeb is on the Editorial Board for the British Journal of Urology International, European Urology, Urology Practice, and Reviews in Urology, and authored the chapter on “Early Detection, Diagnosis, and Staging of Prostate Cancer” for Campbell-Walsh Urology. She also helps teach several courses on prostate cancer for other urologists, and hosts the Men’s Health Show on SiriusXM USA/Canadian satellite radio. Dr. Loeb has a grant from the National Cancer Institute to study the optimal approach to active surveillance.
I am a clinical psychologist with expertise in treating men with prostate cancer and other genitourinary malignancies. As the psychological liaison to Memorial Sloan Kettering’s genitourinary and sexual medicine services, I provide short- and long-term counseling services to patients struggling with cancer-related issues. Men who are undergoing treatment for these diseases sometimes experience treatment-related sexual dysfunction, and I help them and their partners optimize intimacy before, during, and after treatment. I also work with the Center’s 65+ Program, providing psychological support for our patients who are 65 and older, and I co-facilitate a support group for patients dealing with the combined issues of cancer and aging.
Dr. Partin’s laboratories and clinical and surgical interest are focused on development and testing of new and existing methods for predicting the aggressiveness of prostate cancers so that rational treatment decisions can be made by both patients and physicians.
Dr. Partin’s laboratories have investigated many new serum tests, some of which are soon to become available for the diagnosis of prostate cancer as well as basics science investigation of new proteins, which may help in detection, and staging of prostate cancer. In addition, Dr. Partin has an academic and clinical interest in treatment of benign prostatic hyperplasia with an emphasis on minimally invasive techniques for treatment of this common disease of men.
A/Prof. Monique J. Roobol is associate professor and the head of the screening office of the Department of Urology at Erasmus Medical Centre Rotterdam, The Netherlands. She has a master and PhD degree in epidemiology. In the past she worked as a research technician in molecular biology.She is responsible for the Dutch part of the European Randomized study of Screening for prostate cancer (www.erspc.org) and the prostate cancer active surveillance project PRIAS ( www.prias-project.org).
Charles J. Ryan, MD is an Associate Professor of Medicine and Urology at the UCSF Helen Diller Family Comprehensive Cancer Center. where he the Clinical Program Leader for Genitourinary Medical Oncology. He received his MD from the University of Wisconsin in Madison and completed his residency in internal medicine at the University of Wisconsin Hospital and Clinics, where he also served as Chief Resident. He completed a fellowship in medical oncology in the Department of Medicine at Memorial Sloan-Kettering Cancer Center and the Joan and Sanford I. Weill Medical College of Cornell University in New York.
His clinical practice focuses predominantly on advanced prostate cancer as well as germ cell (testicular) tumors and other malignancies of the genitourinary tract.
His clinical and research work centers on the design and conduct of clinical trials of novel therapies for advanced prostate cancer, specifically secondary hormonal therapies targeting adrenal androgen signaling, insulin growth factor inhibitors, androgen receptor targeted therapy and chemotherapy. In addition to clinical trials Dr Ryan collaborates with many laboratories researching the role of the androgen receptor and other signaling mechanisms in prostate cancer patients.
Dr. Sartor is a graduate of Tulane Medical School (1982) and was elected President of the AOA Honor Society. After completing Residency in Internal Medicine at Tulane in 1986, he served as a Fellow in the Medical Oncology Branch of the National Cancer Institute in Bethesda, Maryland. From 1990-1993 he served as a Senior Investigator at the National Cancer Institute in the Clinical Pharmacology Branch where he began to focus on novel therapeutics and clinical trials for advanced prostate cancer patients. He was the Director of the Stanley S. Scott Cancer Center, and served as Chief of the Hematology/Oncology Section at the Louisiana State University (LSU) Health Sciences Center in New Orleans from 1998-2006. After Hurricane Katrina, he departed New Orleans to join the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute/Harvard Medical School in Boston. He returned to Tulane Medical School in 2008 as the Piltz Professor of Cancer Research with a joint appointment in the Departments of Medicine and Urology. He has now been named the LaBorde Professor for Cancer Research. In 2010 he was appointed as the Medical Director of the Tulane Cancer Center.Dr. Sartor’s research and clinical interests have focused broadly on prostate cancer over the past 20 years. His publications range from the genetic studies on prostate cancer, to studies of ethnic populations, to clinical trials involving novel agents. Among other duties, he is past-Chairman of the Integration Panel for the Department of Defense’s Congressionally Directed Medical Research Program in Prostate Cancer and the Medical Oncology Chairman of the GU Oncology Committee at the Radiation Therapy Oncology Group (RTOG). He has lead a number of large international trials in prostate cancer, including those leading to the FDA approval of samarium-153 EDTMP and cabazitaxel.
Chief, Genitourinary Oncology Service; D. Wayne Calloway Chair in Urologic Oncology
Howard I. Scher, MD is Chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center, Professor of Medicine at the Weill Cornell Medical College, and the D. Wayne Calloway Chair in Urologic Oncology. Dr. Scher has helped elucidate key molecular and genetic features of prostate cancer and has translated these insights into the clinical evaluation of novel targeted agents including abiraterone and enzalutamide. His research is focused on the validation of circulating tumor cell and other blood based biomarker assays to biologically profile individual patient tumors to better select and monitor the effects of therapy. Dr. Scher led the international Prostate Cancer Clinical Trials Working Group effort standardize the design and analysis of phase II trials, and serves as the principal investigator of an NIH-supported Specialized Program of Research Excellence in Prostate Cancer, Prostate Cancer Clinical Trials Consortium and the Department of Defense Transformative Impact Award: Toward the Practice of Precision Medicine – A Biomarker Validation Coordinating Center.
Joseph A Smith, Jr. is William L. Bray Professor in the Department of Urologic Surgery at Vanderbilt University in Nashville, Tennessee. He served as Chairman of the department from 1991 to 2015. He is an AOA graduate of the University of Tennessee Medical School and was chosen the Outstanding Graduate. He performed his surgery residency at the University of Texas Southwestern Medical School at Dallas, his urology residency at the University of Utah, and a fellowship in urologic oncology at Memorial Sloan-Kettering Cancer Center in New York.
Dr. Smith has served as President of the American Board of Urology, President of the Society of Urologic Oncology, President of the Southeastern Section of the American Urologic Association, and Chairman of the Residency Review Committee for Urology. He is a recipient of the Distinguished Contribution Award and the Hugh Hampton Young Award from the American Urologic Association and the SUO achievement medal from the Society of Urologic Oncology. He is a member of the American Association of Genitourinary Surgeons and the Clinical Society of GU Surgeons. He was awarded the Outstanding Alumnus Award from the University of Tennessee. Dr. Smith is Editor of the Journal of Urology, the most widely read and highly cited journal in the specialty.
He has published over 300 peer reviewed manuscripts, over 100 book chapters, and has edited or co-edited eight textbooks including the third edition of Hinman’s Atlas of Urologic Surgery. His professional focus has been on innovative treatment strategies for patients with urologic cancers and introduction and evaluation of technologic advances in urologic surgery. He has performed over 1,000 radical cystectomies and 5,000 radical prostatectomies.
Prof Walsh is best known for his 30 years as the Professor and Director of the Brady Urological Institute (1974 – 2004) and for his pioneering work in the development of “the anatomic approach to radical prostatectomy”. He is on the Editorial Board of the New England Journal of Medicine and is a member of the Institute of Medicine of the National Academy of Sciences. For 25 years he was the editor-in-chief of Campbell’s Textbook of Urology, which has been renamed Campbell Walsh in his honour. In 1996, Prof Walsh received the Charles F Kettering Medal from the General Motors Cancer Research Foundation for “the most outstanding recent contributions to the diagnosis and treatment of cancer.” Prof Walsh was honoured as the 2007 National Physician of the Year for Clinical Excellence by America’s Top Doctors®, and was the co-recipient of the 2007 King Faisal International Prize in Medicine. Prof Walsh served as the President of both the American Association of Genitourinary Surgeons and the Clinical Society of Genitourinary Surgeons.
Carl Wijburg (1974) studied Medicine at University of Utrecht (NL). During his medical study his father died of prostate cancer. Therefore he was very motivated to do research into prostate cancer and he worked on the ERSPC project of Prof Schröder in Rotterdam. During his residency he learned the open radical prostatectomy and the first steps of the robot assisted radical prostatectomy on the first daVinci surgical system. In 2007 he followed a training in robotic surgery with Prof. Alex Mottrie in Aalst (B). Since 2008 he works as a urologist in Rijnstate Hospital, Arnhem, the Netherlands. He and his team has performed more than 1,000 radical prostatectomies with the daVinci Si. Carl now trains residents and urologist in RARP and in intracorporeal robot assisted radical cystectomy.
Dr Dingwei Ye is Chairman & Professor of Dept. Urological Surgery ,Fudan University Shanghai Cancer Centre, Vice Chairman, the Committee of Genitourinary Tumor , Chinese Anti-Cancer Association, and Chairman, the Prostate Neoplasm Center, Shanghai Anti-Cancer Association.
Dr. Ye has wide clinical and basic research experiences in Urological Cancer. He has published more than 100 scientific articles in this field as the first author, corresponding author, or co-author in Chinese and American as well as European journals. He undertook Fellowship training in GU Oncology at MD Anderson Cancer Centre and leads both the basic science and clinical urology programs at the world-famous Fudan University Shanghai Cancer Centre.